Reciprocal signaling-metabolic crosstalk between fibroblasts and tumor cells drives cetuximab tolerance in head and neck cancers.

Date publication

juin 2026

Journal

Journal of experimental & clinical cancer research : CR

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BOIDOT Romain

Tous les auteurs :
Vigneron E, Vignau J, Lowyck O, Van den Bossche V, Ambroise J, Kieffer Y, Mechta-Grigoriou F, Rizzi I, Giolito MV, Desgres M, Zaryouh H, Wouters A, Mendola A, Dahou H, Leclerc M, Boidot R, Warnant A, Larondelle Y, Feron O, Machiels JP, Schmitz S, Corbet C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42343427

Résumé

Resistance to EGFR-targeted therapies, including cetuximab, remains a major barrier to effective treatment of head and neck squamous cell carcinoma (HNSCC). Lipid metabolism reprogramming, TGFβ signaling, and cancer-associated fibroblast (CAF) activation have each been linked to cetuximab resistance, but how these processes mechanistically converge remains unclear.

Mots clés

Cancer-associated fibroblasts, Cetuximab, Drug tolerance, Fatty acids, Head and neck cancer, Metabolism, Transforming growth factor beta, Tumor microenvironment

Référence

J Exp Clin Cancer Res. 2026 06 24;: